TD Asset Management
BDTX icon

TD Asset Management’s Black Diamond Therapeutics BDTX Stock Holding History

TD Asset Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-195,930
Closed -$417K – 1227
2026
Q1 		$417K Hold
195,930
– – ﹤0.01% 1181
2025
Q4 		$476K Buy
195,930
+12,510
+7% +$44.3K ﹤0.01% 1174
2025
Q3 		$695K Buy
183,420
+17,742
+11% +$51.9K ﹤0.01% 1142
2025
Q2 		$411K Hold
165,678
– – ﹤0.01% 1146
2025
Q1 		$257K Hold
165,678
– – ﹤0.01% 1186
2024
Q4 		$355K Sell
165,678
-54,000
-25% -$155K ﹤0.01% 1203
2024
Q3 		$929K Sell
219,678
-46,634
-18% -$254K ﹤0.01% 1203
2024
Q2 		$1.24M Buy
266,312
+195,464
+276% +$1.05M ﹤0.01% 1122
2024
Q1 		$359K Buy
+70,848
New +$286K ﹤0.01% 1326

Other funds holding BDTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TD Asset Management's BDTX Position: Q2 2026 in Review

TD Asset Management sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 195,930 shares — an estimated $417K sold.

TD Asset Management first reported a position in BDTX in Q1 2024 and held it in 9 quarters. The position peaked at $1.24M in Q2 2024. 62 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • TD Asset Management reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • TD Asset Management sold 195,930 Black Diamond Therapeutics shares in Q2 2026, an estimated $417K.
  • TD Asset Management first reported a position in Black Diamond Therapeutics in Q1 2024 and held it in 9 quarters.
  • TD Asset Management's Black Diamond Therapeutics position peaked at $1.24M in Q2 2024.
  • 62 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.